EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

NeoACTIVATE Arm C: Phase II trial of neoadjuvant atezolizumab and tiragolumab for high-risk operable Stage III melanoma

Tina J Hieken, David Zahrieh, Thomas J Flotte, Roxana S Dronca, Evidio Domingo-Musibay, Garth D Nelson, Carrie A Strand, Lisa A Kottschade, Heather N Montane, Mara A Piltin, Ruqin Chen, Robert R McWilliams und 8 weitere

European Journal of Cancer · 2025-09 · 227 · 115688

DOI: 10.1016/j.ejca.2025.115688 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift European Journal of Cancer, 2025-09. Verfasst von Tina J Hieken und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Mayo Clinic, Rochester, MN, United States. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Melanoma, Antineoplastic Combined Chemotherapy Protocols, Skin Neoplasms. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Mayo Clinic, Stand up to Cancer, American Association for Cancer Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedMelanomaAntineoplastic Combined Chemotherapy ProtocolsSkin NeoplasmsHumansMaleFemaleMiddle AgedNeoadjuvant TherapyAgedNeoplasm StagingAdultLymph Node Excision

Stichwörter der Autor:innen

AntibodiesAtezolizumabBiomarkersClinical TrialsHumanizedImmunotherapyLymph NodesMelanomaMonoclonalNeoadjuvant TherapyPhase II as TopicProgression-Free SurvivalSkin NeoplasmsT-Lymphocytes

Substanzen

atezolizumabAntibodies, Monoclonal, HumanizedTiragolumab

Autor:innen und Institutionen

  • Department of Surgery, Mayo Clinic, Rochester, MN, United States.
  • Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, United States.
  • Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, United States.
  • Department of Oncology, Mayo Clinic, Jacksonville, FL, United States.
  • Division of Hematology, Oncology, and Transplantation, University of Minnesota, Minneapolis, MN, United States.
  • Department of Oncology, Mayo Clinic, Rochester, MN, United States.

Förderung

  • Mayo Clinic
  • Stand up to Cancer
  • American Association for Cancer Research

Zitieren

APA

Hieken, T. J., Zahrieh, D., Flotte, T. J., Dronca, R. S., Domingo-Musibay, E., Nelson, G. D., Strand, C. A., Kottschade, L. A., Montane, H. N., Piltin, M. A., Chen, R., McWilliams, R. R., Jakub, J. W., Khariwala, S. S., Dudek, A. Z., Johnson, J. E., Markovic, S. N., Dimou, A., Tasche, K. K., & Block, M. S. (2025). NeoACTIVATE Arm C: Phase II trial of neoadjuvant atezolizumab and tiragolumab for high-risk operable Stage III melanoma. European Journal of Cancer, 227, 115688. https://doi.org/10.1016/j.ejca.2025.115688

Vancouver

Hieken TJ, Zahrieh D, Flotte TJ, Dronca RS, Domingo-Musibay E, Nelson GD, et al. NeoACTIVATE Arm C: Phase II trial of neoadjuvant atezolizumab and tiragolumab for high-risk operable Stage III melanoma. European Journal of Cancer. 2025;227:115688. doi:10.1016/j.ejca.2025.115688

BibTeX
@article{Hieken2025,
  author = {Hieken, Tina J and Zahrieh, David and Flotte, Thomas J and Dronca, Roxana S and Domingo-Musibay, Evidio and Nelson, Garth D and Strand, Carrie A and Kottschade, Lisa A and Montane, Heather N and Piltin, Mara A and Chen, Ruqin and McWilliams, Robert R and Jakub, James W and Khariwala, Samir S and Dudek, Arkadiusz Z and Johnson, Jeffrey E and Markovic, Svetomir N and Dimou, Anastasios and Tasche, Kendall K and Block, Matthew S},
  title = {NeoACTIVATE Arm C: Phase II trial of neoadjuvant atezolizumab and tiragolumab for high-risk operable Stage III melanoma},
  journal = {European Journal of Cancer},
  year = {2025},
  volume = {227},
  pages = {115688},
  doi = {10.1016/j.ejca.2025.115688}
}
Kostenlos starten →